Serum vitamin D, vitamin D binding protein, and lung cancer survival

Lung Cancer

Volumn 86, Issue 3, 2014, Pages 297-303

  Anic, Gabriella M ^a   Weinstein, Stephanie J ^a   Mondul, Alison M ^a   Männistö, Satu ^b   Albanes, Demetrius ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

25 hydroxyvitamin d; Cohort; Lung cancer; Serum vitamin d; Survival; Vitamin d binding protein

Indexed keywords

25 HYDROXYVITAMIN D; ALPHA TOCOPHEROL; BETA CAROTENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; VITAMIN D; VITAMIN D BINDING PROTEIN; 25-HYDROXYVITAMIN D;

ADULT; AGED; ARTICLE; CALCIUM INTAKE; CALORIC INTAKE; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVOR; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FAT INTAKE; FEMALE; FOLLOW UP; HUMAN; LEISURE; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEASONAL VARIATION; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL TIME; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; DIET THERAPY; LUNG TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL;

AGED; ALPHA-TOCOPHEROL; BETA CAROTENE; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84961288794     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.10.008     Document Type: Article

References (42)

1. American Cancer Society Cancer Facts and Figures 2013, http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013.
2. Porojnicu A.C., Robsahm T.E., Dahlback A., Berg J.P., Christiani D., Bruland O.S., et al. Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role?. Lung Cancer 2007, 55(3):263-270.
3. Lim H.S., Roychoudhuri R., Peto J., Schwartz G., Baade P., Moller H. Cancer survival is dependent on season of diagnosis and sunlight exposure. Int J Cancer 2006, 119(7):1530-1536.
4. Nakagawa K., Kawaura A., Kato S., Takeda E., Okano T. 1 alpha,25-dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 2005, 26(2):429-440.
5. Nakagawa K., Sasaki Y., Kato S., Kubodera N., Okano T. 22-Oxa-1 alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005, 26(6):1044-1054.
6. Jiang F., Bao J., Li P., Nicosia S.V., Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem 2004, 279(51):53213-53221.
7. Holick M.F. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009, 19(2):73-78.
8. Toriola A.T., Nguyen N., Scheitler-Ring K., Colditz G.A. Circulating 25-hydroxyvitamin D levels and prognosis among cancer patients: a systematic review. Cancer Epidemiol Biomark Prev 2014, 23(6):917-933.
9. Tretli S., Schwartz G.G., Torjesen P.A., Robsahm T.E. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control 2012, 23(2):363-370.
10. Zhou W., Heist R.S., Liu G., Asomaning K., Neuberg D.S., Hollis B.W., et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol 2007, 25(5):479-485.
11. Heist R.S., Zhou W., Wang Z., Liu G., Neuberg D., Su L., et al. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol 2008, 26(34):5596-5602.
12. Liu Y., Chen W., Hu Z.B., Xu L., Shu Y.Q., Pan S.Y., et al. Plasma vitamin D levels and vitamin D receptor polymorphisms are associated with survival of non-small cell lung cancer. Chin J Cancer Res 2011, 23(1):33-37.
13. Speeckaert M., Huang G., Delanghe J.R., Taes Y.E. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006, 372(1-2):33-42.
14. Chun R.F. New perspectives on the vitamin D binding protein. Cell Biochem Funct 2012, 30(6):445-456.
15. Nagasawa H., Uto Y., Sasaki H., Okamura N., Murakami A., Kubo S., et al. Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity. Anticancer Res 2005, 25(6A):3689-3695.
16. Metcalf J.P., Thompson A.B., Gossman G.L., Nelson K.J., Koyama S., Rennard S.I., et al. Gcglobulin functions as a cochemotaxin in the lower respiratory tract. A potential mechanism for lung neutrophil recruitment in cigarette smokers. Am Rev Respir Dis 1991, 143(4 Pt 1):844-849.
17. Weinstein S.J., Stolzenberg-Solomon R.Z., Kopp W., Rager H., Virtamo J., Albanes D. Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Cancer Res 2012, 72(5):1190-1198.
18. Weinstein S.J., Mondul A.M., Kopp W., Rager H., Virtamo J., Albanes D. Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer 2013, 132(12):2940-2947.
19. Mondul A.M., Weinstein S.J., Virtamo J., Albanes D. Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. Br J Cancer 2012, 107(9):1589-1594.
20. Mondul A.M., Weinstein S.J., Moy K.A., Mannisto S., Albanes D. Vitamin D-binding protein, circulating vitamin D and risk of renal cell carcinoma. Int J Cancer 2014, 134(11):2699-2706.
21. The ATBC Cancer Prevention Study Group The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994, 330(15):1029-1035.
22. Pietinen P., Hartman A.M., Haapa E., Rasanen L., Haapakoski J., Palmgren J., et al. Reproducibility and validity of dietary assessment instruments. I. A self-administered food use questionnaire with a portion size picture booklet. Am J Epidemiol 1988, 128(3):655-666.
23. Weinstein S.J., Yu K., Horst R.L., Parisi D., Virtamo J., Albanes D. Serum 25-hydroxyvitamin D and risk of lung cancer in male smokers: a nested case-control study. PLoS ONE 2011, 6(6):e20796.
24. Korhonen P., Malila N., Pukkala E., Teppo L., Albanes D., Virtamo J. The Finnish Cancer Registry as follow-up source of a large trial cohort - accuracy and delay. Acta Oncol 2002, 41(4):381-388.
25. Ersfeld D.L., Rao D.S., Body J.J., Sackrison J.L., Miller A.B., Parikh N., et al. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 2004, 37(10):867-874.
26. Fears T.R., Ziegler R.G., Donaldson J.L., Falk R.T., Hoover R.N., Stanczyk F.Z., et al. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. Cancer Epidemiol Biomark Prev 2000, 9(4):403-412.
27. Al-oanzi Z.H., Tuck S.P., Raj N., Harrop J.S., Summers G.D., Cook D.B., et al. Assessment of vitamin D status in male osteoporosis. Clin Chem 2006, 52(2):248-254.
28. Bouillon R., Van Assche F.A., Van Baelen H., Heyns W., De Moor P. Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration. J Clin Investig 1981, 67(3):589-596.
29. Gallicchio L., Helzlsouer K.J., Chow W.H., Freedman D.M., Hankinson S.E., Hartge P., et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010, 172(1):10-20.
30. Turner A.M., McGowan L., Millen A., Rajesh P., Webster C., Langman G., et al. Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology. Eur Respir J 2013, 41(2):410-416.
31. Hansdottir S., Monick M.M., Hinde S.L., Lovan N., Look D.C., Hunninghake G.W. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 2008, 181(10):7090-7099.
32. Menezes R.J., Cheney R.T., Husain A., Tretiakova M., Loewen G., Johnson C.S., et al. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomark Prev 2008, 17(5):1104-1110.
33. Kim S.H., Chen G., King A.N., Jeon C.K., Christensen P.J., Zhao L., et al. Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer 2012, 77(2):265-271.
34. Matsunawa M., Amano Y., Endo K., Uno S., Sakaki T., Yamada S., et al. The aryl hydrocarbon receptor activator benzoapyrene enhances vitamin D3 catabolism in macrophages. Toxicol Sci 2009, 109(1):50-58.
35. Scragg R., Camargo C.A. Frequency of leisure-time physical activity and serum 25-hydroxyvitamin D levels in the US population: results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2008, 168(6):587-591. 577-86; discussion.
36. Brock K., Cant R., Clemson L., Mason R.S., Fraser D.R. Effects of diet and exercise on plasma vitamin D (25(OH)D) levels in Vietnamese immigrant elderly in Sydney, Australia. J Steroid Biochem Mol Biol 2007, 103(3-5):786-792.
37. Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., Holick M.F. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000, 72(3):690-693.
38. Arem H., Moore S.C., Park Y., Ballard-Barbash R., Hollenbeck A., Leitzmann M., et al. Physical activity and cancer-specific mortality in the NIH-AARP Diet and Health Study cohort. Int J Cancer 2014, 135(2):423-431.
39. McTiernan A. Mechanisms linking physical activity with cancer. Nat Rev Cancer 2008, 8(3):205-211.
40. Sonderman J.S., Munro H.M., Blot W.J., Signorello L.B. Reproducibility of serum 25-hydroxyvitamin d and vitamin D-binding protein levels over time in a prospective cohort study of black and white adults. Am J Epidemiol 2012, 176(7):615-621.
41. Hofmann J.N., Yu K., Horst R.L., Hayes R.B., Purdue M.P. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomark Prev 2010, 19(4):927-931.
42. Jorde R., Sneve M., Hutchinson M., Emaus N., Figenschau Y., Grimnes G. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol 2010, 171(8):903-908.